X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211622
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206817
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215761
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207477
https://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/cipla-recalls-7228-bottles-of-overactive-bladder-treatment-drug-in-america/articleshow/84725538.cms?from=mdr
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-21-2021-1626855243.pdf
https://www.business-standard.com/article/news-cm/zydus-cadila-receives-usfda-final-approval-for-solifenacin-succinate-tablets-120102000337_1.html#:~:text=Zydus%20Cadila%20has%20received%20final,5%20mg%20and%2010%20mg.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cadila-gets-usfda-nod-for-overactive-bladder-treatment-drug/articleshow/78762823.cms
https://www.prnewswire.com/news-releases/fda-approves-vesicare-ls-solifenacin-succinate-oral-suspension-for-pediatric-patients-301066339.html
https://www.prnewswire.com/news-releases/fda-approves-first-treatment-for-a-form-of-bladder-dysfunction-in-pediatric-patients-as-young-as-2-years-of-age-301065609.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213346
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-25-2020-1585131468.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211423
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211423
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-suspends-sale-of-ranitidine-tab-in-us/articleshow/71324636.cms
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/strides-pharma-science-arm-gets-usfda-nod-for-drug-to-treat-overactive-bladder/articleshow/71324069.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211701
https://www.business-standard.com/article/pti-stories/glenmark-pharma-gets-usfda-nod-for-overactive-bladder-treatment-drug-119052100196_1.html
https://www.moneycontrol.com/news/business/alembic-pharma-gets-usfda-nod-for-overactive-bladder-treatment-drug-3998621.html
https://www.business-standard.com/article/companies/orchid-pharma-says-closer-to-resolution-as-rp-has-received-three-plans-119052000277_1.html
https://www.moneycontrol.com/news/business/glenmark-pharma-gets-usfda-nod-for-overactive-bladder-treatment-drug-3997731.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211657
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209333
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205483
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209239
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210688
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209839
https://www.pharmacompass.com/pdf/news/vesicare-solifenacin-succinate-astellas-pharma-inc-v-aurobindo-pharma-1529990564.pdf
https://www.tga.gov.au/prescription-medicines-registration-new-generic-medicines-and-biosimilar-medicines
https://www.prnewswire.com/news-releases/fda-approves-supplemental-new-drug-application-for-myrbetriq-mirabegron-for-use-in-combination-with-solifenacin-succinate-for-the-treatment-of-overactive-bladder-symptoms-300644079.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207721
http://www.prnewswire.com/news-releases/us-fda-accepts-for-review-astellas-supplemental-new-drug-application-for-mirabegron-for-use-in-combination-with-solifenacin-succinate-5-mg-for-the-treatment-of-overactive-bladder-300518426.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205483
http://www.prnewswire.com/news-releases/astellas-submits-supplemental-new-drug-application-for-mirabegron-for-use-in-combination-with-solifenacin-succinate-5-mg-for-the-treatment-of-overactive-bladder-300482309.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209239
http://www.pharmatimes.com/news/astellas_and_gedeon_named_for_abpi_code_breaches_1195055
http://www.fiercebiotech.com/biotech/allergan-chases-high-dose-low-side-effects-alzheimer-s-combo-biotech-buy
http://www.eurekalert.org/pub_releases/2015-03/uab-mha030215.php
Market Place
Share 
